SOD1 and amyotrophic lateral sclerosis: The evolving therapeutic landscape for ALS is undergoing a significant transformation, which is marked by the landmark approval of Tofersen, the first gene-targeted therapy specially designed for patients with a mutation in the SOD1 gene.